Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 4/20 | 0.61 |
| ▸ | ANPEP | P15144 | 3/20 | 0.61 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.60 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
| ▸ | PTPRC | P08575 | 1/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylalanine SCHEMBL4958178 | 0.80 | SLC7A5 (0.85) | LAP3ANPEPSLC15A1ALPIPKM | |
| Dl-Phenylalanine SCHEMBL4958176 | 0.80 | SLC7A5 (0.85) | LAP3ANPEPSLC15A1ALPIPKM | |
| SCHEMBL9041162 | 0.79 | LAP3 (0.51) | LAP3ANPEPSLC15A1ACP3 | |
| SCHEMBL28115263 | 0.79 | LAP3 (0.51) | LAP3ANPEPSLC15A1ACP3 | |
| Phenylalanine Amide SCHEMBL15467554 | 0.79 | ALPI (0.63) | LAP3ANPEPSLC15A1ALPIPKM | |
| Dl-Phenylalanine SCHEMBL7645387 | 0.79 | SLC7A5 (0.81) | LAP3ANPEPSLC15A1ALPIPKM | |
| Phenylalanine SCHEMBL7645389 | 0.79 | SLC7A5 (0.81) | LAP3ANPEPSLC15A1ALPIPKM | |
| SCHEMBL12323250 | 0.78 | SLC7A5 (0.68) | LAP3ANPEPSLC15A1ALPIPKM | |
| SCHEMBL28110902 | 0.78 | ALPI (0.68) | LAP3ANPEPSLC15A1ALPIPKM | |
| SCHEMBL5060967 | 0.78 | ALPI (0.68) | LAP3ANPEPSLC15A1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897759-B2 | Metabolically stable puromycin analogs | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) | 2011-03-01 | — | — | US | disclosed |
| US-20090069556-A1 | METABOLICALLY STABLE PUROMYCIN ANALOGS | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069556-A1 | METABOLICALLY STABLE PUROMYCIN ANALOGS | PDF, NPEPPS, RNMT | LAP3 1258/4885ANPEP 351/4885SLC15A1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.